CD40-Ligand lacking native-pattern glycosylation

Details CD40-Ligand lacking native-pattern glycosylation CD40-Ligand lacking native-pattern glycosylation

2008-07-29

2008-07-29

Gambel, Phillip (Department: 1644)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Reexamination Certificate

active

07405270

ABSTRACT:
There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor and lack native-pattern glycosylation.

REFERENCES:
patent: 5057417 (1991-10-01), Hammonds et al.
patent: 5110730 (1992-05-01), Edgington et al.
patent: 5182368 (1993-01-01), Ledbetter et al.
patent: 5185441 (1993-02-01), Wallner et al.
patent: 5247069 (1993-09-01), Ledbetter et al.
patent: 5474771 (1995-12-01), Lederman et al.
patent: 5506126 (1996-04-01), Seed et al.
patent: 5540926 (1996-07-01), Aruffo et al.
patent: 5565321 (1996-10-01), Spriggs et al.
patent: 5573924 (1996-11-01), Beckmann et al.
patent: 5716805 (1998-02-01), Srinivasan
patent: 5817516 (1998-10-01), Kehry et al.
patent: 5843728 (1998-12-01), Seed et al.
patent: 5876950 (1999-03-01), Siadak et al.
patent: 5961974 (1999-10-01), Armitage et al.
patent: 5962406 (1999-10-01), Armitage et al.
patent: 5981724 (1999-11-01), Armitage et al.
patent: 6087329 (2000-07-01), Armitage et al.
patent: 6264951 (2001-07-01), Armitage et al.
patent: 6290972 (2001-09-01), Armitage et al.
patent: 6391637 (2002-05-01), Armitage et al.
patent: 6410711 (2002-06-01), Armitage et al.
patent: 6793924 (2004-09-01), Lederman et al.
patent: 0315062 (1989-05-01), None
patent: 0330191 (1989-08-01), None
patent: 0555880 (1993-08-01), None
patent: 0585943 (1994-03-01), None
patent: 0595659 (1994-04-01), None
patent: 0897983 (2003-05-01), None
patent: 0832229 (2004-01-01), None
patent: 0667901 (2004-08-01), None
patent: WO 93/08207 (1993-04-01), None
patent: WO 93/09812 (1993-05-01), None
patent: WO 93/23550 (1993-11-01), None
patent: WO 94/10308 (1994-11-01), None
Armitage, R. et al., “Molecular and biological characterization of a murine ligand for CD40,”Nature357: 80-82, 1992.
Aruffo, A. and Seed, B., “Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system,”Proc. Natl. Acad. Sci. USA 84: 8573-8577, Dec. 1987.
Banchereau, J. and Roussett, F., “Establishing long-term human B-cell lines,”Clinical Immunology Spectrum 3(3):9-11, 1991.
Banchereau, J. et al, “Long-term human B cell lines dependent on interleukin-4 and antibody to CD40,”Science 251: 70-72, 1991.
Casamayor-Palleja, M. et al., “A subset of CD4+memory T cells contains preformed CD40 ligand that is rapidly but transiently expressed on their surface after activation through the T cell receptor complex,”J. Exp. Med. 181: 1293-1302, 1995.
Clark, E. and Ledbetter J., “Activation of human B cells mediated through two distinct cell surface antigens, Bp35 and Bp50,”Proc. Natl. Acad. Sci. USA 83: 4494-4498, 1986.
Covey, L.R. et al., “Isolation of cDNAs encoding T-BAM, a surface glycoprotein on CD4+T cells mediating contact-dependent helper function for B cells: identity with the CD40-ligand,”Mol Immunol. 31(6): 471-484, 1994.
Durie, F. et al., “Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40,”Science 261: 1328-1330, 1993.
Fanslow, W. et al., “Soluble forms of CD40 inhibit biologic responses of human B cells,”J. Immunol. 149: 655-660, 1992.
Farrah, T. and Smith, C., “Emerging cytokine family,”Nature 358: 26, 1992.
Gascan, H. et al., “Anti-CD40 monoclonal antibodies or CD4+T cell clones and IL-4 induce IgG4 and IgE switching in purified human B cells via different signaling pathways,”J. Immunol. 147(1): 8-13, 1991.
Ghaderi, A. et al., “Affinity-purified soluble FcεRII/Cd23 derived from a culture supernatant of an EBV-immortalized B-cell line induced a monophasic fever in rabbits,”Immunology 73:510-511, 1991.
Gordon, J. et al., “Resting B lymphocytes can be triggered directly through the CDw40 (Bp50) antigen,”J. Immunol. 140(5): 1425-1430, 1988.
Gordon, J. et al., “Synergistic interaction between interleukin 4 and anti-Bp50 (CDw40) revealed in a novel B cell restimulation assay,”Eur J. Immunol. 17: 1535-1538, 1987.
Graf, D. et al., “Cloning of TRAP, a ligand for CD40 on human T cells,”Eur J. Immunol. 22: 3191-3194, 1992.
HLDA Antibody Database—Antibodies assigned to CD154, 1998.
Hollenbaugh, D. et al., “The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity,”EMBO J 11(12): 4313-4321, 1992.
Jabara, H. et al., “CD40 and IgE: Synergism between anti-CD40 monoclonal antibody and interleukin 4 in the induction of IGE synthesis by highly purified human B cells,”J. Exp. Med. 172:1861, 1990.
Kikutani, H. et al., “Molecular structure of human lymphocyte receptor for immunoglobulin E,”Cell 47:657-665, 1986.
Lauzon, G. et al., “Characterization of gp-39, a B-Lymphocyte associated differentiation antigen which is also present on granulocytes and macrophages,”Mol. Immunol. 25(9):829-841, 1988.
Lederman, S. et al., “Identification of a novel surface protein on activated CD4+T cells that induces contact-dependent B cell differentiation (HELP),”J Exp Med 175:1091-1101, 1992.
Liu, Y-J. et al., “Mechanism of antigen-driven selection in germinal centres,”Nature342:929-931, 1989.
Noelle, R. et al., “CD4- and its ligand, an essential ligand-receptor pair for thymus-dependent B-cell activation,”Immunol Today 13:431-433, 1992.
Noelle, R. et al., “A 39-kDa protein on activated belper T cells binds CD40 and transduces the signal for cognate activation of B cells,”Proc Natl. Acad. Sci. USA 89:6550-6554, 1992.
Oslund et al., “Immunoadsorbents,” In Encyclopedia of Immunology, Roitt & Delves, Eds., Academic Press 1992, pp. 776-778.
Paulie, S. et al., “The human B lymphocyte and carcinoma antigen, Cdw40 is a phospoprotein involved in growth signal transduction,”J. Immunol. 142(2): 590-595, 1989.
Potocnik, A. et al., “Expression of activation antigens on T cells in rheumatoid arthritis patients,”Scand. J. Immunol. 31:213-224, 1990.
Riordan, M.L. et al., “Oligonucleotide-based therapeutics,”Nature 350:442-443, 1991.
Rousset, F. et al., “Cytokine-induced proliferation and immunoglobulin production of human B lymphocytes triggered through their CD40 antigen,”J. Exp. Med. 173: 705-710, 1991.
Spriggs, M. et al., “Recombinant human cd40 ligand stimulates B cell proliferation and immunoglobulin E secretion,”J. Exp. Med. 176: 1543-1550, 1992.
Stamenkovic, I. Et al., “A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas,”EMBO J. 8(5): 1403-1410, 1989.
Valle, A. et al., “Activation of human B lymphocytes through CD40 and interleukin 4,”Eur. J. Immunol. 19: 1463-1467, 1989.
Wang, F. et al., “Epstein-Barr virus nuclear protein 2 transactivates a cis-Acting CD23 DNA element,”J. Virol. 65(8): 4101-4106, 1991.
Zettlmeissl, G. et al., “Expression and characterization of human CD4: immunoglobulin fusion proteins,”DNA Cell Biol. 9(5):347-353, 1990.
Zhang, K. et al., “CD40 stimulation provides an IFN-γ-independent and IL-4 dependent differentiation signal directly to human B cells for IgE production,”J. Immunol. 146(6): 1836-1842, 1991.
6thInternational Workshop and Conference on Human Leukocyte Differentiation Antigens (Nov. 10-14, 1996) Kobe Japan, Abstract #381, Program TC-3-01, Armitage et al., (Oct. 1996).
6thInternational Workshop and Conference on Human Leukoycte Differentiation Antigens, Kobe Japan, Proceedings, Fanslow et al. pp. 101-103 (Nov. 10-14, 1996).
6thInternational Workshop and Conference on Human Leukocyte Differentiation Antigens Kobe Japan, Abstracts vol. 48, No. 4—Part II, p. 477, TC-3-01 to TC-3-

Affiliated with

Also associated with

Rating

CD40-Ligand lacking native-pattern glycosylation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with CD40-Ligand lacking native-pattern glycosylation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CD40-Ligand lacking native-pattern glycosylation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2784868